Cargando…

Triple therapy in COPD: understanding the data

Effectiveness of single-inhaler triple therapy on exacerbation risk and mortality in COPD is exaggerated in IMPACT and ETHOS trials from confounding by prior ICS discontinuation: effectiveness fades in analyses and studies with no prior ICS discontinuation https://bit.ly/3tOgNdW

Detalles Bibliográficos
Autor principal:	Suissa, Samy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2023
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885273/ https://www.ncbi.nlm.nih.gov/pubmed/36726367 http://dx.doi.org/10.1183/23120541.00615-2022

Ejemplares similares

Single-Inhaler Triple versus Dual Bronchodilator Therapy in COPD: Real-World Comparative Effectiveness and Safety
por: Suissa, Samy, et al.
Publicado: (2022)

Randomized Trials Built on Sand: Examples from COPD, Hormone Therapy, and Cancer
por: Suissa, Samy
Publicado: (2012)

Current appraisal of single inhaler triple therapy in COPD
por: Lipworth, Brian, et al.
Publicado: (2018)

Inhaled Corticosteroid Withdrawal in Chronic Obstructive Pulmonary Disease: Can IMPACT Help?
por: Suissa, Samy
Publicado: (2020)

Cardiovascular disease and COPD: dangerous liaisons?
por: Rabe, Klaus F., et al.
Publicado: (2018)

Triple therapy (ICS/LABA/LAMA) in COPD: thinking out of the box
por: Vanfleteren, Lowie E.G.W., et al.
Publicado: (2019)

Inhaled corticosteroids in COPD and the risk of serious pneumonia
por: Suissa, Samy, et al.
Publicado: (2013)

Appropriate use of inhaled corticosteroids in COPD: the candidates for safe withdrawal
por: Yawn, Barbara P, et al.
Publicado: (2016)

Impact of triple therapy on mortality in COPD
por: Soumagne, Thibaud, et al.
Publicado: (2023)

The need to further understand who gets hospitalized for a COPD exacerbation
por: Maselli, Diego J, et al.
Publicado: (2012)

Antifibrotics and Reduced Mortality in Idiopathic Pulmonary Fibrosis: Immortal Time Bias
por: Suissa, Samy, et al.
Publicado: (2022)

Effect of triple therapy in patients with asthma-COPD overlap
por: Ishiura, Yoshihisa, et al.
Publicado: (2019)

The Number Needed to Treat: 25 Years of Trials and Tribulations in Clinical Research
por: Suissa, Samy
Publicado: (2015)

Mortality in IMPACT: Confounded by Asthma?
por: Suissa, Samy
Publicado: (2020)

Dual versus triple therapy in patients hospitalized for COPD in France: a claims data study
por: Dalon, Faustine, et al.
Publicado: (2019)

Outcome of Inhaler Withdrawal in Patients Receiving Triple Therapy for COPD
por: Kim, Sae Ahm, et al.
Publicado: (2016)

Symptomatic burden of COPD for patients receiving dual or triple therapy
por: Chen, Stephanie, et al.
Publicado: (2018)

Comparative effectiveness of triple therapy versus dual bronchodilation in COPD
por: Voorham, Jaco, et al.
Publicado: (2019)

Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD
por: Bourbeau, Jean, et al.
Publicado: (2021)

Is once enough? Understanding the preferences of COPD and asthma patients for once- versus twice-daily treatment
por: Horne, Rob
Publicado: (2013)

The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses
por: Dixon, William G, et al.
Publicado: (2011)

Icenticaftor, Novel Therapy for COPD: This Glass Is Half Full
por: Rennard, Stephen I.
Publicado: (2023)

The role of cognitive behavioural therapy in living well with COPD
por: Heslop-Marshall, Karen, et al.
Publicado: (2019)

Are Drug Eluting Stents Worth Triple Therapy?
por: Heidenreich, Paul
Publicado: (2017)

The reasons for triple therapy in stable COPD patients in Japanese clinical practice
por: Miyazaki, Masaki, et al.
Publicado: (2015)

The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK
por: Brusselle, Guy, et al.
Publicado: (2015)

Initiation of triple therapy maintenance treatment among patients with COPD in the US
por: Simeone, Jason C, et al.
Publicado: (2016)

The IMPACT of triple versus dual single-inhaler therapy on exacerbations of COPD
por: Dobler, Claudia C.
Publicado: (2018)

Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal
por: Vanfleteren, Lowie, et al.
Publicado: (2018)

Preventing clinically important deterioration with single-inhaler triple therapy in COPD
por: Naya, Ian, et al.
Publicado: (2018)

Erratum: Outcome of Inhaler Withdrawal in Patients Receiving Triple Therapy for COPD
Publicado: (2016)

Living with COPD: the struggle for breath and for lung volume reduction therapies
por: Mahadeva, Ravi, et al.
Publicado: (2018)

Nurse-led cognitive behavioural therapy for treatment of anxiety in COPD
por: Yohannes, Abebaw Mengistu
Publicado: (2018)

Metformin and the Risk of Cancer: Time-related biases in observational studies
por: Suissa, Samy, et al.
Publicado: (2012)

Response to Comment on: Smiechowski et al. The Use of Metformin and the Incidence of Lung Cancer in Patients With Type 2 Diabetes. Diabetes Care 2013;36:124–129
por: Suissa, Samy, et al.
Publicado: (2013)

Response to Bodmer et al. Metformin and the Risk of Cancer: Time-Related Biases in Observational Studies. Diabetes Care 2012;35:2665–2673
por: Suissa, Samy, et al.
Publicado: (2013)

Response to Yang and Chan. Metformin and the Risk of Cancer: Time-Related Biases in Observational Studies. Diabetes Care 2012;35:2665–2673
por: Suissa, Samy, et al.
Publicado: (2013)

More Data on Risks and Outcomes of COVID-19 in Asthma, COPD, and Bronchiectasis
por: Chung, Kian Fan
Publicado: (2021)

Advances in understanding COPD
por: Anderson, Gary P.
Publicado: (2016)

Indices and COPD
por: Howard, Peter
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_kqqlgh81enkv67hb0f8a55931v